Figure S2 from Glutamate Decarboxylase 65 Signals through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer

Yi Gao,Lu Chen,ZunGuo Du,WenChao Gao,ZhengMing Wu,XiuJuan Liu,Hai Huang,DanFeng Xu,QingQuan Li

DOI: https://doi.org/10.1158/0008-5472.22421264.v1

2023-01-01

Abstract:Figure S2 shows increased GAD65 enzymatic activity caused by phosphorylation at serine 6

What problem does this paper attempt to address?

Figure S5 from Glutamate Decarboxylase 65 Signals through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer

Yi Gao,Lu Chen,ZunGuo Du,WenChao Gao,ZhengMing Wu,XiuJuan Liu,Hai Huang,DanFeng Xu,QingQuan Li

DOI: https://doi.org/10.1158/0008-5472.22421255.v1

2023-01-01

Abstract:Figure S5 shows the effects of GAD65 knockdown on CRPC growth and progression
Figure S1 from Glutamate Decarboxylase 65 Signals through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer

Yi Gao,Lu Chen,ZunGuo Du,WenChao Gao,ZhengMing Wu,XiuJuan Liu,Hai Huang,DanFeng Xu,QingQuan Li

DOI: https://doi.org/10.1158/0008-5472.22421267.v1

2023-01-01

Abstract:Figure S1 shows increased GABA shunt activity in CRPC
Figure S3 from Glutamate Decarboxylase 65 Signals Through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer

Yi Gao,Lu Chen,ZunGuo Du,WenChao Gao,ZhengMing Wu,XiuJuan Liu,Hai Huang,DanFeng Xu,QingQuan Li

DOI: https://doi.org/10.1158/0008-5472.22421261.v1

2023-01-01

Abstract:Figure S3 shows the impact of GAD65 knockdown on ATP levels or lipid/RNA biosynthesis of CRPC
Figure S4 from Glutamate Decarboxylase 65 Signals through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer

Yi Gao,Lu Chen,ZunGuo Du,WenChao Gao,ZhengMing Wu,XiuJuan Liu,Hai Huang,DanFeng Xu,QingQuan Li

DOI: https://doi.org/10.1158/0008-5472.22421258.v1

2023-01-01

Abstract:Figure S4 shows the binding of GABA, the product of GAD65, to AR in CRPC
Glutamate Decarboxylase 65 Signals Through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer.

Yi Gao,Lu Chen,ZunGuo Du,WenChao Gao,ZhengMing Wu,XiuJuan Liu,Hai Huang,DanFeng Xu,QingQuan Li

DOI: https://doi.org/10.1158/0008-5472.can-19-0700

IF: 11.2

2019-01-01

Cancer Research

Abstract:AbstractThe transition from an androgen-dependent to a castration-resistant state is a critical event in the progression of prostate cancer. In this study, we compared metabolic pathways between isogenic human androgen-dependent and castration-resistant prostate cancer (CRPC) patient-derived xenograft models, and found consistent activation of the γ-aminobutyric acid (GABA) shunt in CRPC. This difference was the result of phosphorylation and activation of glutamate decarboxylase 65 (GAD65), which synthesizes GABA from glutamate by decarboxylation. Mechanistic investigation showed that GABA binds to and retains the androgen receptor (AR) in the nucleus by facilitating AR association with the nuclear zinc finger protein ZNHIT3. GAD65 knockdown decreased the growth of multiple established CRPC xenografts and markedly delayed the time to emergence of castration resistance. These data encourage exploring GAD65 as a therapeutic target for CRPC.Significance:This study reports metabolic alterations that could be responsible for the development of CRPC and identifies the GABA-producing enzyme GAD65 as a potential new therapeutic target.See related commentary by Taylor and Watt, p. 4580
USP54 is a potential therapeutic target in castration-resistant prostate cancer

Cheng Zhou,Xuehu Zhang,Hangbin Ma,Yinghao Zhou,Yibo Meng,Chenchen Chen,Guowei Shi,Wandong Yu,Jun Zhang

DOI: https://doi.org/10.1186/s12894-024-01418-7

2024-01-01

BMC Urology

Abstract:Background USP54, a ubiquitin-specific protease in the deubiquitinase (DUB) family, facilitates the malignant progression of several types of cancer. However, the role of USP54 in prostate cancer (PCa), especially castration-resistant prostate cancer (CRPC), remains unknown. Methods We established the CRPC LNCaP-AI cell line from the hormone-sensitive prostate cancer (HSPC) LNCaP cell line. RNA-Seq was utilized to explore DUB expression levels in LNCaP and LNCaP-AI. USP54 was knocked down, and its effects on cell growth were evaluated in vitro and in vivo. Bioinformatics analyses were conducted to explore signaling pathways affected by USP54 in PCa. Quantitative polymerase chain reaction was used to confirm key signaling pathways involved. Results USP54 was the most strongly upregulated DUB in LNCaP-AI cells compared with LNCaP cells. USP54 levels were higher in PCa than in normal tissues. USP54 silencing suppressed the proliferation of PCa cell lines, both in vitro and in vivo. USP54 expression was positively correlated with the androgen receptor (AR) signaling level in PCa samples, and USP54 knockdown inhibited AR signaling in PCa cells. Conclusions USP54 was upregulated during HSPC progression to CRPC. USP54 depletion suppressed CRPC cell proliferation both in vitro and in vivo. USP54 may facilitate PCa progression by regulating AR signaling.
Supplementary Materials and Methods from Glutamate Decarboxylase 65 Signals through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer

Yi Gao,Lu Chen,ZunGuo Du,WenChao Gao,ZhengMing Wu,XiuJuan Liu,Hai Huang,DanFeng Xu,QingQuan Li

DOI: https://doi.org/10.1158/0008-5472.22421252.v1

2023-01-01

Abstract:Supplementary Materials and Methods shows the Extended materials and methods used in this study
Altered glucuronidation deregulates androgen dependent response profiles and signifies castration resistance in prostate cancer

Brenna M. Zimmer,Michelle E. Howell,Linlin Ma,Jeffrey R. Enders,Danielle Lehman,Eva Corey,Joseph J. Barycki,Melanie A. Simpson

DOI: https://doi.org/10.18632/oncotarget.28059

2021-09-14

Oncotarget

Abstract:Glucuronidation controls androgen levels in the prostate and the dysregulation of enzymes in this pathway is associated with castration resistant prostate cancer. UDP-glucose dehydrogenase (UGDH) produces UDP-glucuronate, the essential precursor for glucuronidation, and its expression is elevated in prostate cancer. We compared protein and metabolite levels relevant to the glucuronidation pathway in five prostate cancer patient-derived xenograft models paired with their isogenic counterparts that were selected in vivo for castration resistant (CR) recurrence. All pairs showed changes in UGDH and associated enzymes and metabolites that were consistent with those we found in an isogenic androgen dependent (AD) and CR LNCaP prostate cancer model. Ectopic overexpression of UGDH in LNCaP AD cells blunted androgen-dependent gene expression, increased proteoglycan synthesis, significantly increased cell growth compared to controls, and eliminated dose responsive growth suppression with enzalutamide treatment. In contrast, the knockdown of UGDH diminished proteoglycans, suppressed androgen dependent growth irrespective of androgens, and restored androgen sensitivity in CR cells. Importantly, the knockdown of UGDH in both LNCaP AD and CR cells dramatically sensitized these cells to enzalutamide. These results support a role for UGDH in androgen responsiveness and a target for therapeutic strategies in advanced prostate cancer.
Supplementary Figures S1-S6 from Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer Via Its Promotion of Intratumoral Androgen Biosynthesis

Li Xiao,Yuliang Wang,Ke Xu,Hao Hu,Zhenyu Xu,Dinglan Wu,Zhu Wang,Wenxing You,Chi‐Fai Ng,Shuhui Yu,F.H.Y. Chan

DOI: https://doi.org/10.1158/0008-5472.22419014.v1

2023-01-01

Abstract:Supplementary Figures S1-S6
Supplementary Figure 4 from Αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer Through JNK1-Mediated Activation of Androgen Receptor

Huimin Lu,Tao Wang,Jing Li,Carmine Fedele,Qin Liu,Jianzhong Zhang,Zhong Jiang,Dhanpat Jain,Renato V. Iozzo,Shelia M. Violette,Paul H. Weinreb,Roger J. Davis,Daniel Gioeli,Thomas J. FitzGerald,Dario C. Altieri,Lucia R. Languino

DOI: https://doi.org/10.1158/0008-5472.22412969.v1

2023-01-01

Abstract:Full-size scans of PSA and androgen receptor immunoblots shown in Figure 4.
Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer.

Tian-Zhong Yan,Feng-Shuo Jin,Li-Ping Xie,Long-Cheng Li

DOI: https://doi.org/10.1159/000144067

2008-01-01

Urologia Internationalis

Abstract:Objective: To study the role of the glucocorticoid receptor (GR) signal pathway and downstream cytokine interleukin-6 (IL-6) in androgen-independent growth of prostate cancer ( PC). Methods: The human androgen-dependent PC (ADPC) cell line LNCaP and androgen-independent PC (AIPC) cell line DU145 were cultured in vitro. Immunocytochemistry was used to examine the expression of the androgen receptor (AR), GR, HSP90 and IL-6. The GR antagonist RU486 was used to treat cultured cells, and the effects of RU486 on the proliferation of both cell lines were analyzed by MTT assay. Expression of HSP90 and IL-6 mRNA and protein was assessed by RT-PCR and Western blots, respectively. Results: LNCaP cells were AR-positive and GR-negative, whereas DU145 cells were GR-positive and AR-negative. The expression of HSP90 and IL-6 in DU145 cells were significantly stronger than that in LNCaP cells (p < 0.01). RU486 had no obvious effects on the growth of LNCaP cells, but exerted a significant time- and dose-dependent growth inhibition on DU145 cells at doses as low as 0.1 mu mol/l. RU486 treatment of DU145 cells also resulted in a dose-dependent decrease in the expression of HSP90 and IL-6 mRNA and protein. Conclusions: The GR signal pathway may be the main survival pathway for DU145 cells. Abnormal hyperactivation of the GR signal pathway and its promoting the expression of HSP90 and IL-6 contribute to the progression of ADPC to AIPC after androgen ablation. Copyright (c) 2008 S. Karger AG, Basel.
Phosphorylation of the androgen receptor at Ser81 is co‐sustained by CDK1 and CDK9 and leads to AR‐mediated transactivation in prostate cancer

XinTao Gao,Jiaqian Liang,LiYang Wang,Zhaoyang Zhang,Penghui Yuan,Jiaxin Wang,Yanfei Gao,Fen Ma,Carla Calagua,Huihui Ye,Olga Voznesensky,Shaogang Wang,Tao Wang,Jihong Liu,Shaoyong Chen,Xiaming Liu

DOI: https://doi.org/10.1002/1878-0261.12968

2021-05-03

Molecular Oncology

Abstract:Androgen receptor (AR) is the principal molecule in prostate cancer (PCa) etiology and therapy. AR reactivation still remains a major challenge during treatment of castration‐resistant prostate cancer (CRPC) tumors that relapse after castration therapies. Recent reports have indicated the enrichment of Ser81‐phosphorylated AR (pS81) in the nucleus of CRPC cells, and CDK1 and CDK9 as the kinases phosphorylating AR at S81. In the current study we showed that pS81 is preferentially localized in the nucleus in both rapid biopsy metastatic CRPC samples and PCa xenografts, and nuclear pS81 localization correlated with AR transactivation in tumor xenografts. Chromatin immunoprecipitation (ChIP) analysis demonstrated an alignment of S81 phosphorylation and AR‐mediated transactivation with the chromatin locus openness. Moreover, pS81‐specific ChIP‐Seq showed a disproportional occupancy of pS81 on AR‐activated promoters, while 3C‐ChIP assays further indicated an enrichment of pS81 at the PSA enhancer‐promoter loop, a known AR activating hub. In the latter, CDK9 was shown to modulate the transactivation of the AR and RNA Pol II. Indeed, ChIP and re‐ChIP assays also confirmed that AR‐dependent activation of the PSA enhancer and promoter mediated by pS81 was coupled with activation of Pol II and the pTEFb complex. Mechanistically, we determined that CDK1 and CDK9 sustained the pS81 AR modification in the soluble and chromatin‐bound fractions of PCa cells, respectively. Finally, we demonstrated that CDK1 activity was maintained throughout the cell cycle, and that CDK1 inhibitors restored androgen sensitivity in CRPC tumor cells. Based on these findings, CDK1 and CDK9 could be targeted as pS81 kinases in patients with CRPC, either alone or in conjunction with direct AR antagonists.

oncology
Supplementary Figure 5 from Αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer Through JNK1-Mediated Activation of Androgen Receptor

Huimin Lu,Tao Wang,Jing Li,Carmine Fedele,Qin Liu,Jianzhong Zhang,Zhong Jiang,Dhanpat Jain,Renato V. Iozzo,Shelia M. Violette,Paul H. Weinreb,Roger J. Davis,Daniel Gioeli,Thomas J. FitzGerald,Dario C. Altieri,Lucia R. Languino

DOI: https://doi.org/10.1158/0008-5472.22412966

2023-01-01

Abstract:alphavbeta6 enhances AR transcriptional activity in LNCaP cells.
Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo

Niki Zacharias,Jaehyuk Lee,Sumankalai Ramachandran,Sriram Shanmugavelandy,James McHenry,Prasanta Dutta,Steven Millward,Seth Gammon,Eleni Efstathiou,Patricia Troncoso,Daniel E. Frigo,David Piwnica-Worms,Christopher J Logothetis,Sankar N Maity,Mark A Titus,Pratip Bhattacharya

DOI: https://doi.org/10.1007/s11307-018-1199-6

2018-05-10

Molecular Imaging and Biology

Abstract:PurposeAndrogen receptor (AR) signaling affects prostate cancer (PCa) growth, metabolism, and progression. Often, PCa progresses from androgen-sensitive to castration-resistant prostate cancer (CRPC) following androgen-deprivation therapy. Clinicopathologic and genomic characterizations of CRPC tumors lead to subdividing CRPC into two subtypes: (1) AR-dependent CRPC containing dysregulation of AR signaling alterations in AR such as amplification, point mutations, and/or generation of splice variants in the AR gene; and (2) an aggressive variant PCa (AVPC) subtype that is phenotypically similar to small cell prostate cancer and is defined by chemotherapy sensitivity, gain of neuroendocrine or pro-neural marker expression, loss of AR expression, and combined alterations of PTEN, TP53, and RB1 tumor suppressors. Previously, we reported patient-derived xenograft (PDX) animal models that contain characteristics of these CRPC subtypes. In this study, we have employed the PDX models to test metabolic alterations in the CRPC subtypes.ProceduresMass spectrometry and nuclear magnetic resonance analysis along with in vivo hyperpolarized 1-[13C]pyruvate spectroscopy experiments were performed on prostate PDX animal models.ResultsUsing hyperpolarized 1-[13C]pyruvate conversion to 1-[13C]lactate in vivo as well as lactate measurements ex vivo, we have found increased lactate production in AR-dependent CRPC PDX models even under low-hormone levels (castrated mouse) compared to AR-negative AVPC PDX models.ConclusionsOur analysis underscores the potential of hyperpolarized metabolic imaging in determining the underlying biology and in vivo phenotyping of CRPC.

radiology, nuclear medicine & medical imaging
Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging

Ziqi Zhu,Yoon-Mi Chung,Olga Sergeeva,Vladimir Kepe,Michael Berk,Jianneng Li,Hyun-Kyung Ko,Zhenfei Li,Marianne Petro,Frank P DiFilippo,Zhenghong Lee,Nima Sharifi

DOI: https://doi.org/10.1074/jbc.RA118.004846

2018-11-16

Abstract:Androgens such as testosterone and dihydrotestosterone are a critical driver of prostate cancer progression. Cancer resistance to androgen deprivation therapies ensues when tumors engage metabolic processes that produce sustained androgen levels in the tissue. However, the molecular mechanisms involved in this resistance process are unclear, and functional imaging modalities that predict impending resistance are lacking. Here, using the human LNCaP and C4-2 cell line models of prostate cancer, we show that castration treatment-sensitive prostate cancer cells that normally have an intact glucuronidation pathway that rapidly conjugates and inactivates dihydrotestosterone and thereby limits androgen signaling, become glucuronidation deficient and resistant to androgen deprivation. Mechanistically, using CRISPR/Cas9-mediated gene ablation, we found that loss of UDP glucuronosyltransferase family 2 member B15 (UGT2B15) and UGT2B17 is sufficient to restore free dihydrotestosterone, sustained androgen signaling, and development of castration resistance. Furthermore, loss of glucuronidation enzymatic activity was also detectable with a nonsteroid glucuronidation substrate. Of note, glucuronidation-incompetent cells and the resultant loss of intracellular conjugated dihydrotestosterone were detectable in vivo by 18F-dihydrotestosterone PET. Together, these findings couple a mechanism with a functional imaging modality to identify impending castration resistance in prostate cancers.
Supplementary Figure 1 from Αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer Through JNK1-Mediated Activation of Androgen Receptor

Huimin Lu,Tao Wang,Jing Li,Carmine Fedele,Qin Liu,Jianzhong Zhang,Zhong Jiang,Dhanpat Jain,Renato V. Iozzo,Shelia M. Violette,Paul H. Weinreb,Roger J. Davis,Daniel Gioeli,Thomas J. FitzGerald,Dario C. Altieri,Lucia R. Languino

DOI: https://doi.org/10.1158/0008-5472.22412978

2023-01-01

Abstract:Increased alphavbeta6 integrin and JNK expression and enhanced JNK nuclear localization in castrated mice.
Inhibition of GLS Suppresses Proliferation and Promotes Apoptosis in Prostate Cancer

Junfeng Zhang,Shiyu Mao,Yadong Guo,Yuan Wu,Xudong Yao,Yong Huang

DOI: https://doi.org/10.1042/bsr20181826

2019-01-01

Bioscience Reports

Abstract:Altered glutamine metabolism is a hallmark of cancer growth, forming the theoretical basis for development of metabolic therapies as cancer treatments. Glutaminase (GLS), a crucial enzyme involved in the regulation of glutamine metabolism, has been reported to play crucial roles in cancer development. However, the precise function of GLS in prostate cancer (PCa) remains unclear. The purpose of the present study was to assess the GLS expression and its clinical significance in PCa. We found that GLS was significantly up-regulated in PCa tissues and cell lines. High expression of GLS was significantly associated with Gleason score (P=0.001) and Tumor stage (P=0.015). Functionally, we silenced GLS in PCa cell lines and revealed that GLS knockdown largely blunted the proliferation of DU145 and PC-3 cells. Mechanistically, we demonstrated that knockdown of GLS induced apoptosis and cell cycle arrest. Moreover, we observed that the expressions of Bax were increased while the levels of cyclinD1 and Bcl-2 were decreased after knockdown of GLS in PCa cells. Importantly, through Western blot analysis, we identified that GLS knockdown dramatically suppressed Wnt/β-catenin pathway. Taken together, GLS is a novel oncogene in PCa and may be a potential treatment target for PCa patients.
A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance

Yuning Liao,Yuan Liu,Zhenlong Shao,Xiaohong Xia,Yuanfei Deng,Jianyu Cai,Leyi Yao,Jinchan He,Cuifu Yu,Tumei Hu,Wenshuang Sun,Fang Liu,Daolin Tang,Jinbao Liu,Hongbiao Huang

DOI: https://doi.org/10.1038/s41388-021-01851-0

IF: 8.756

2021-06-02

Oncogene

Abstract:Prostate cancer (PC) is the second most common cancer with limited treatment option in males. Although the reactivation of embryonic signals in adult cells is one of the characteristics of cancer, the underlying protein degradation mechanism remains elusive. Here, we show that the molecular chaperone GRP75 is a key player in PC cells by maintaining the protein stability of SIX1, a transcription factor for embryonic development. Mechanistically, GRP75 provides a platform to recruit the deubiquitinating enzyme USP1 to inhibit K48-linked polyubiquitination of SIX1. Structurally, the C-terminus of GRP75 (433-679 aa) contains a peptide binding domain, which is required for the formation of GRP75-USP1-SIX1 protein complex. Functionally, pharmacological or genetic inhibition of the GRP75-USP1-SIX1 protein complex suppresses tumor growth and overcomes the castration resistance of PC cells in vitro and in xenograft mouse models. Clinically, the protein expression of SIX1 in PC tumor tissues is positively correlated with the expression of GRP75 and USP1. These new findings not only enhance our understanding of the protein degradation mechanism, but also may provide a potential way to enhance the anti-cancer activity of androgen suppression therapy.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Supplementary Figure 4 from p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis

Jian Zhong,Liya Ding,Laura R. Bohrer,Yunqian Pan,Ping Liu,Jun Zhang,Thomas J. Sebo,R. Jeffrey Karnes,Donald J. Tindall,Jan van Deursen,Haojie Huang

DOI: https://doi.org/10.1158/0008-5472.22400846

2023-01-01

Abstract:PDF file - 78KB, Western blot analysis of ectopically v5-tagged cyclin B1 and CDK1 in 293T cells.
Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer

Wei-Yu Chen,Tao Zeng,Yu-Chng Wen,Hsiu-Lien Yeh,Kuo-Ching Jiang,Wei-Hao Chen,Qingfu Zhang,Jiaoti Huang,Yen-Nien Liu

DOI: https://doi.org/10.1016/j.canlet.2018.10.004

IF: 9.756

2019-01-01

Cancer Letters

Abstract:Androgen receptor (AR) targeting is an important therapeutic strategy for treating prostate cancer. Most tumors progress to castration-resistant prostate cancer (CRPC) and develop the neuroendocrine (NE) phenotype under androgen deprivation therapy (ADT). The molecular basis for NE transdifferentiation after ADT remains incompletely understood. Herein, we show that an immunocyte expression protein, ZBTB46, induces inflammatory response gene expression and contributes to NE differentiation of prostate cancer cells. We demonstrated a molecular mechanism whereby ZBTB46 can be regulated by the androgen-responsive gene, SPDEF, and is associated with NE prostate cancer (NEPC) differentiation. In addition, ZBTB46 acts as a transcriptional coactivator that binds to the promoter of prostaglandin-endoperoxide synthase 1 (PTGS1) and transcriptionally regulated PTGS1 levels. Overexpression of ZBTB46 decreases the sensitivity of the combination of enzalutamide and a PTGS1 inhibitor; however, knockdown of ZBTB46 sensitizes the PTGS1 inhibitor and reduces tumor malignancy. ZBTB46 is inversely correlated with SPDEF and is increased in higher tumor grades and small-cell NE prostate cancer (SCNC) patients, which are positively associated with PTGS1. Our findings suggest that the induction of ZBTB46 results in increased PTGS1 expression, which is associated with NEPC progression and linked to the dysregulation of the AR-SPDEF pathway.

oncology

Figure S2 from Glutamate Decarboxylase 65 Signals through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer

Figure S5 from Glutamate Decarboxylase 65 Signals through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer

Figure S1 from Glutamate Decarboxylase 65 Signals through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer

Figure S3 from Glutamate Decarboxylase 65 Signals Through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer

Figure S4 from Glutamate Decarboxylase 65 Signals through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer

Glutamate Decarboxylase 65 Signals Through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer.

USP54 is a potential therapeutic target in castration-resistant prostate cancer

Supplementary Materials and Methods from Glutamate Decarboxylase 65 Signals through the Androgen Receptor to Promote Castration Resistance in Prostate Cancer

Altered glucuronidation deregulates androgen dependent response profiles and signifies castration resistance in prostate cancer

Supplementary Figures S1-S6 from Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer Via Its Promotion of Intratumoral Androgen Biosynthesis

Supplementary Figure 4 from Αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer Through JNK1-Mediated Activation of Androgen Receptor

Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer.

Phosphorylation of the androgen receptor at Ser81 is co‐sustained by CDK1 and CDK9 and leads to AR‐mediated transactivation in prostate cancer

Supplementary Figure 5 from Αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer Through JNK1-Mediated Activation of Androgen Receptor

Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo

Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging

Supplementary Figure 1 from Αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer Through JNK1-Mediated Activation of Androgen Receptor

Inhibition of GLS Suppresses Proliferation and Promotes Apoptosis in Prostate Cancer

A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance

Supplementary Figure 4 from p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis

Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer